New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:15 EDTBDSIBioDelivery Sciences randomized half the patients required for Clonidine study
BioDelivery Sciences International announced that it has randomized more than half of the planned number of patients required for its ongoing initial Phase 3 study of Clonidine Topical Gel, BDSI's proposed treatment for painful diabetic neuropathy. The intent of the study will be to demonstrate the efficacy and safety of Clonidine Topical Gel for the treatment of PDN. An interim analysis of the study, which will be based on the first 50% of patients entering the study, is now anticipated to occur in the Q3 of 2014. It was earlier projected based on estimated patient enrollment the interim analysis would occur in fourth quarter of this year. The purpose of the interim analysis is to confirm the assumptions regarding the study sample size and allow for an increase if needed.
News For BDSI From The Last 14 Days
Check below for free stories on BDSI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
07:34 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information
August 12, 2014
07:11 EDTBDSIBioDelivery Sciences and Endo Pharmaceuticals report on BEMA Buprenorphine NDA
Subscribe for More Information
August 8, 2014
09:00 EDTBDSIBioDelivery Sciences still a takeover target, says Janney Capital
Janney Capital continues to believe that BioDelivery Sciences (BDSI) could be a takeover target, noting that it thinks partner Endo International (ENDP) could be a potential buyer if BioDelivery has more positive top-line results and if the market weakens. The firm, which added that it likes BioDelivery Sciences as a stand-alone company as well, maintains its Buy rating and $15 fair value estimate on the stock.
August 7, 2014
17:29 EDTBDSIBioDelivery Sciences sees U.S. launch of Bunavail in late Q3
Subscribe for More Information
17:27 EDTBDSIBioDelivery Sciences reports Q2 EPS (14c), consensus (13c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use